Anti-HIV orally dissolvable strips - Oak Therapeutics
Latest Information Update: 28 Jul 2023
At a glance
- Originator Oak Therapeutics
- Developer Oak Therapeutics; University of Kansas Medical Center
- Class Antiretrovirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in HIV-infections(In children, Prevention) in Kenya (PO, Film)
- 12 Jun 2019 Oak Therapeutics co-operates with University of Kansas Medical Center for development of orally dissolvable strips for HIV infections (In children, Prevention) in Kenya
- 12 Jun 2019 Preclinical development in HIV infections (In children, Prevention) in Kenya (PO)